Moderna’s Hold Rating: Navigating Revenue Adjustments and Product Development Uncertainties

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Moderna on August 1 and set a price target of $31.00.

Terence Flynn’s rating is based on a combination of factors including Moderna’s recent financial performance and future projections. Although the company’s second-quarter revenues exceeded expectations by $30 million, the revenue guidance for 2025 was lowered by $300 million at the high end due to delays in UK vaccine deliveries. This adjustment in revenue expectations, despite the company’s efforts in expense management and cost savings, contributes to the Hold rating.
Additionally, while Moderna is making progress in various vaccine trials and maintaining productive interactions with the FDA, the timing of data releases and product launches, such as the CMV and COVID/flu combo vaccines, introduces uncertainty. The company’s ongoing efforts to manage costs, including a planned workforce reduction, are positive, but the overall outlook remains cautious given the revised revenue guidance and the timeline for key product developments. These factors collectively justify the Hold rating as the company navigates these challenges.

In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $27.00 price target.